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Abstract: The bacterial nitroreductase NfnB has been the focus of a great deal of research for its use in
directed enzyme prodrug therapy in combination with the nitroreductase prodrug CB1954 with this
combination of enzyme and prodrug even entering clinical trials. Despite some promising results,
there are major limitations to this research, such as the fact that the lowest reported Km for this
enzyme far exceeds the maximum dosage of CB1954. Due to these limitations, new enzymes are now
being investigated for their potential use in directed enzyme prodrug therapy. One such enzyme that
has proved promising is the YfkO nitroreductase from Bacillus Licheniformis. Upon investigation,
the YfkO nitroreductase was shown to have a much lower Km (below the maximum dosage) than that
of NfnB as well as the fact that when reacting with the prodrug it produces a much more favourable
ratio of enzymatic products than NfnB, forming more of the desired 4-hydroxylamine derivative
of CB1954.
Keywords: cancer; nitroreductase; prodrug; CB1954; DEPT
1. Introduction
Cancer chemotherapy is an area of research that is of the utmost importance with
cancer being responsible for over 30% of global deaths each year [1,2]. To increase the tu-
mour selectivity of cancer chemotherapy treatments and combat the problem of systematic
toxicity, alternative treatment methods being explored involve the use of prodrugs [3–7]. One
chemotherapy strategy that is currently being investigated involving the use of prodrugs
is directed enzyme prodrug therapy (DEPT), this strategy involves delivering prodrug-
activating enzymes directly to a tumour site before administering a prodrug, thereby
activating the prodrug to its more pharmaceutically active products at the cancer site [6]. A
variety of delivery vectors have been explored for potential DEPT application, including
antibodies (ADEPT) [8,9], viruses (VDEPT) [10] and genes (GDEPT) [11–14]. We are inves-
tigating a novel form of DEPT that utilizes gold coated magnetic nanoparticles (AuMNP)
as the delivery vector for genetically modified prodrug activating enzymes called magnetic
nanoparticle directed enzyme prodrug therapy (MNDEPT) [15,16].
Nitroreductases (NTRs) are flavin mononucleotide (FMN) containing enzymes [17–19]
which have been strongly implicated for a potential role in cancer prodrug therapy due to
their ability to reduce organic nitroaromatic compounds such as the prodrug 5-(aziridin-1-
yl)-2,4-dinitrobenzamide (CB1954) [20–24]. The CB1954 prodrug undergoes the reduction of
one of its nitro groups to hydroxylamine derivatives in the presence of an NTR with NADH
or NADPH present as a cofactor [24], the schematic of this reduction is presented in Figure 1.
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The 4-hydroxylamine derivative from the reduction reacts with intracellular thioesters,
such as acetyl CoA, to form a highly cytotoxic product that causes DNA interstrand
cross-linking resulting in rapid cell death [8,24]. It is important to note however that the
2-hydroxylamine derivative itself is also highly toxic and exhibits a greater bystander
effect than the 4-hydroxylamine but as it does not react to form a DNA cross-linking
species it is the less desirable product of the two. Thus, the discovery and development of
nitroreductases that preferentially generate the 4-hydroxylamine derivative, rather than
the 2-hydroxylamine product, is another area of research that is of growing interest [24,25].
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The most heavily studied NTR for use in DEPT is NfnB from Escherichia coli commonly
referred to in the literature as the “bacterial nitroreductase”. The NfnB-CB1954 combination
has even progressed to the clinical trial stage using the GDEPT model, with some positive
results being seen for both prostate and ovarian cancers [26,27]. Despite some promising
results, the fact that the E. coli NfnB has an extremely low turnover rate of the prodrug
and the highest achievable plasma concentration of CB1954 is less than one eightieth of
the lowest reported Km value for E. coli NfnB is a major limitation to this research [8,11].
The YfkO nitroreductase from Bacillus licheniformis has been shown in the literature to be
a promising candidate to move forward within DEPT strategies, due to it h ving a much
high r turnover of CB1954 when compared to NfnB as well as bei g superior with regard
to the efficiency of its reaction with the prodrug [14,28].
This aim of this study is to make a direct comparison between the E. coli NfnB and
the B. Licheniformis YfkO in terms of their suitability for use in MNDEPT treatments. We
will be directly comparing the kinetic parameters and cell kill potential of the enzymes
directly and when immobilized onto AuMNPs in order to assess their suitability for use in
MNDEPT [15,29,30].
2. Materials and Methods
All chemicals and reagents were purchased from Sigma Aldrich (Gillingham, UK)
unless otherwise stated.
2.1. Protein Expression and Purification
A yfko-cys or nfnb-cys gene (dependent on desired enzyme) that had been previously
cloned into the pET28a(+) (Novagen, Merck, UK) expression vector, was transformed into
an E. coli Rosetta strain B21 DE3 (Novagen, Merck, UK) and the expression and purification
of the gen tically modified enzymes was performed as previously described [15]. A colony
of E. coli Rosetta which contained the expression vector with the relevant enzyme gene,
was added to a Luria-Bertani (LB) inoculant tube (5 mL) inoculated with kanamycin
(50 µg/mL). The inoculant tube was then vortexed overnight at 1500 rpm for 16 h. After
this 16 h period the inoculant was added to a flask containing LB expression medium
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(500 mL) and kanamycin (50 µg/mL). This expression medium was left to grow until it
had reached an optical density of 0.6–0.7 measured at 590 nm, after which expression of
protein was induced by adding isopropyl-β-D-thio-galactoside (IPTG) (2 mL, 100 mM).
The culture was harvested after 4 h of nitroreductase expression by centrifugation (9318 rcf,
10 min, 4 ◦C). Expressed nitroreductase was released from cells by sonicating the cell pellet
in imidazole (10 mm, pH 7.2) for 2 min on ice. The desired enzyme was purified from the
cell debris first by centrifugation (44,800 relative centrifugal force (rcf), 1 h) and passing
the subsequent supernatant through a metal ion affinity chromatography column using
Ni2+, with imidazole as the eluent. Eluted protein was incubated on ice for 1 h with flavin
mononucleotide to ensure enzyme active site saturation. Impurities were removed from the
solution via size exclusion chromatography with a PD10 column using phosphate buffer
(50 mM, pH 7.2) as the eluent. A 12% SDS-PAGE was used to assess the purity and weight
of the purified proteins, using Coomassie blue as the stain visualizer. The Bradford assay
using a BSA standard curve was performed to assess the protein concentration, this was
done according to the manufacturer’s instructions.
2.2. Enzyme Reactivity with CB1954
The purified enzyme’s reactivity towards the CB1954 prodrug was determined as pre-
viously described [15]. Briefly, enzyme (25 mg/mL) was incubated with NADPH (300 µM)
and CB1954 (100 µM) in phosphate buffer (PB) (50 mM, pH 7.2) and absorbance spectra
(200–800 nm) was measured every 90 s for 15 min on a Jasco V-550, UV-vis spectropho-
tometer. For active enzyme/CB1954 combinations, product formation was measured at
420 nm [15,31].
2.3. CB1954 Kinetics
CB1954 kinetic experiments were all carried out in a 96-well microtiter plate (Corning,
USA) using a Thermoscientific Varioskan 96-well plate microplate reader using the method
that we have previously described [32–34]. Product formation was measured at 420 nm
over time to determine the -Menten kinetic parameters of the CB1954 prodrug with either
NfnB-Cys or YfkO-Cys. CB1954 (0.1–10 mM), NADH (400 µM) and PB (50 mM, pH 7.2)
were combined and incubated at 37 ◦C for 3 min before purified NfnB-Cys or YfkO-
Cys (10 µg/mL). Hydroxylamine yield per second was determined by calculating the
change in absorbance over 20 s and the molar extinction coefficient, which is the same for
both products (ε = 1200 M−1 cm−1 at 420 nm) [12,13,15,25,32]. Data was analysed using
SigmaPlot 12 (SPSS, Systat Software Inc., Chicago, USA) where a non-linear regression tool
was used to generate a Michaelis-Menten hyperbolic curve and a report containing the
important kinetic information of the system under test. Coefficient of Variability (CoV) for
the kinetics is 7.06%.
2.4. HPLC Analysis
All HPLC experiments were carried out on a UHPLC machine (Dionex Ultimate 3000
HPLC system, ThermoScientific, Waltham, MA, USA) using a C18 column for analysis
(Waters Spherisorb® 5 µm ODS2 4.6 mm × 250 mm C18 column, Wilmslow, UK) following
the method previously described [31,32]. HPLC runs were performed with the instrument
set to the following parameters: 50 µL injection volume, a fixed column oven temperate of
25 ◦C, a run length of 45 min and the UV wavelength for detection was 420 nm [31,32,34].
Owing to the light sensitive nature of some of the reagents, samples that were designated
for HPLC were prepared in 15 mL amber falcon tubes as follows: NADH (120 µL, 10 mM)
nitroreductase (116 µg/mL), CB1954 (20 µL, 50 mM) then made to a final volume of 1080 µL
using PB (50 mM, pH 7.2). The reaction mixture was incubated at 25 ◦C for 15 min, and then
degassed under nitrogen (g) for 15 min, giving a total reaction time of 30 min. Following
the completion of the reaction time, 750 µL of the de-gassed reaction was pipetted into
a chromacol select 2 mL vial (2-SVW8-CPK) and placed into the HPLC machine. The
solvent ratio used for all HPLC runs was a 10:90 ratio of acetonitrile/water at a ratio,
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for the first 20 min of the HPLC run the acetonitrile concentration was increased by 1%
per minute to a ratio of 30:70 at the 20 min timepoint. Following this 20 min time point
the acetonitrile concentration was altered to keep increasing by 40% per minute to reach
a concentration of 100% acetonitrile after 22 min. Results were analysed and validated
against literature values and standard spectrum scans at 420 nm of CB1954 (20 µL, 50 mM),
NADH (120 µL, 10 mM), and nitroreductase (116 ug/mL), spectrum scans can be found
within Supplementary Materials. Ratios of the 2′ and 4′-hydroxylamine products were
determined at 420 nm, where both products have equal absorbance. CoV for the HPLC
is 5.25%.
2.5. Cell Viability Assays
Cell viability assays were performed as previously described [32–34]. SK-OV-3 (ECACC
91091004) ovarian cancer cells (Sigma–Aldrich, Gillingham, UK) were seeded into a 96-well
plate (corning, Corning, NY, USA) at a density of 1 × 103 cells per well, in 100 µL Dul-
becco’s Modified Eagles Medium (DMEM) containing 10% Fetal Bovine Serum (FBS), 1%
penicillin/streptomycin and 1% L-glutamine, and were left to attach to the plate in a 5%
CO2 incubator at 37 ◦C overnight. After 16 h, the medium was carefully aspirated off,
and fresh medium containing increasing concentrations of 25 to 200 nM of enzyme or
immobilized enzyme (50 µL) was added to the wells along with CB1954 (100 µM). Wells
where only enzyme or immobilized enzyme (200 nM), CB1954 (10 µM) or DMEM (100 µL)
were added served as controls with the final volume in each wellbeing 100 µL. After
4 h in a CO2 incubator at 37 ◦C, the medium was removed, and cells were replenished
with fresh complete DMEM (100 µL). After 48 h, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (20 µL, 5 mg/mL) was added to each well and incubated at
37 ◦C for 4 h. Culture medium was carefully aspirated, the purple formazan crystals that
formed were then dissolved in Dimethyl sulfoxide (DMSO) (100 µL) and the absorbance
was read at 570 nm in a Thermo Scientific Varioskan 96-well plate microplate reader. CoV
for the cell culture is 2.76%.
2.6. Synthesis and Purification of AuMNPs
Fe3O4 nanoparticles (220 µL, 3 mg/mL) were added to sodium citrate dihydrate
(4.5 mL, 100 mM) in deionized water (145.5 mL) and degassed in argon for 30 min, following
degassing the mixture was magnetically stirred for the remainder of the reaction. After
the reaction had been stirring for 30 min, Au seeds (1 mL) were then slowly added to the
mixture before being left to stir for another hour. HAuCl4 (5 mL, 1% by weight) was then
added slowly at a rate of 1 mL per minute and left to stir for 5 min, NH2OH (1 mL, 200 mM)
was then added at 0.5 mL per minute and the reaction was left to stir for an hour at 60 ◦C.
Sodium citrate dihydrate (4.5 mL, 100 mM) was then added and the reaction was stirred
for an hour before being removed from the reaction vessel and centrifuged for an hour at
1270 rcf and 20 ◦C. The supernatant was then extracted from the centrifuge tubes without
disturbing the pellet, placed into 8 mL glass vials and magnetically separated using a
50 × 50 × 25 mm 1T Neodymium magnet (First4magnets, Tuxford, UK). The final step of
the purification was to centrifuge the AuMNPs at 500 rcf for 2 h to allow full separation
of the AuMNPs and any uncoated Fe3O4 nanoparticles. CoV for the AuMNP synthesis
is 26.06%.
2.7. Conjugation of Cys-Tagged Enzymes to Au-MNPs
Magnetically purified AuMNPs, suspended in sodium citrate dihydrate (1 mM,
pH 7.4), were incubated with a volume of the enzyme at a ratio of 1 AuMNP:270 en-
zymes to achieve a monolayer coating of the nanoparticles [15]. The volume of enzyme
incubated with AuMNPs was determined based upon the concentration calculated using
the Bradford assay and the concentration and size of AuMNPs as determined by UV-
Vis [15]. Nano-conjugates were left to form at 4 ◦C for 48 h. A full wavelength UV-Vis scan
(450–650 nm) was performed on AuMNPs before and after conjugation, to observe any
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changes in the gold peak caused by conjugation. A successful conjugation is indicated by a
redshift of 3–5 nm of the λ-max of the gold peak [15,35].
2.8. Characterisation of AuMNPs and Subsequent Conjugates
Magnetically purified AuMNPs were sent to Cardiff University for TEM analysis
to assess particle morphology. Briefly, 5 mL of purified particles, suspended in sodium
citrate (1 mM, pH 7.4), were dried down onto formvar/carbon coated 300 mesh grids
and examined and imaged in a Philips CM12 TEM (FEI U. K. Ltd., Cambridge, UK) at
80 kV and images captured with a Megaview III camera and AnalySIS software v. 3.1
(Soft Imaging System GmbH, Münster, Germany). Particle size was measured with ImageJ
software. Next, AuMNPs and subsequent AuMNP-NTR conjugates were assessed using
UV-Vis spectroscopy as per our previous work [15,33]. Briefly, a full spectrum UV-Vis scan
was obtained of the synthesised nanoparticles, before and after being conjugated to an
enzyme, to observe any changes in the λ-max of the gold peak that would indicate the
successful formation of an enzyme monolayer on the particle surface.
Finally, cyclic voltammetry was used to confirm if the binding of the cys-tagged
enzymes to a gold surface was occurring via thiol bonds as planned. All measurements
were performed using an Autolab PGSTAT 30 computer-controlled electrochemical mea-
surement system (Eco Chemie, Utrecht, Holland). The analysis was carried out with a
three-electrode cell; using a saturated calomel electrode (SCE) as the reference electrode
and a platinum counter electrode. The working electrode was an enzymatically modified
gold coated glass slide. Prior to the formation of the enzyme layer, the gold coated glass
slides (Winkler GmbH, Stuttgart, Germany) were flame annealed resulting in a flat gold
surface with strong Au (111) characteristics [36]. Two gold slides were then incubated glass
back to the glass back in the purified desalted NTR for 48 h at 5 ◦C. The electrode cell was
purged with nitrogen for 20 min prior to running and the cell was placed in the faraday
cage and the software was run using the following parameters: scan 0.0 V to −1.2 V at
50 mV/s and scanned twice. The data was then collected and processed using Ecochemie
GPES software and presented using Microsoft Excel.
3. Results
3.1. Protein Expression and Purification
The recombinant proteins were all purified using metal ion affinity chromatography
(IMAC). As observed previously, both cys-tagged enzymes required a higher concentration
of imidazole to be eluted than their his-only counterparts [15]. The purity and molecular
weight of each protein was determined before use in further experiments. Molecular
weights of the proteins were established using SDS-PAGE and protein concentrations were
determined using the Bradford method and expressions generally yielded 2–5 mg/mL
pure protein.
3.2. Characterization of AuMNPs and Subsequent Conjugates
A TEM image of the synthesis and purified AuMNPs was obtained, and it was
established that the sample contained predominately AuMNPs with a small amount of
uncoated Fe3O4 the sample (Figure 2).
The figure shows that the particles are spherical in shape and have an average size
of approximately 50 nm, with a standard deviation of ±11 nm from a sample size of
30 nanoparticles. As can be seen in the figure, there is a very low count of uncoated Fe3O4
nanoparticles from the sample that had yet to undergo final centrifugation purification.
Next, AuMNPs were conjugated with either NfnB-cys or YfkO-cys at a ratio of 1:270, as
per our previous published work [15]. A full spectrum UV-Vis scan was performed before
and after conjugation to look for any changes in the λ-max of the gold peak (Figure 3).
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blue line represents the AuMNPs prior to conjugation (λ-max = 536 nm) and the orange line represents the AuMNP-NTR
conjugate (λ-max = 540 nm).
Figure 3 is an overlay of the scans obtained before and after conjugation, where the
blue line represents AuMNP and the orange line represents AuMNP immobilised YfkO-
cys. The λ-max of the gold peak prior to conjugation is 536 nm. Then, once enzymes are
conjugated onto the surface of the nanoparticles, there is a redshift in the λ-max to give a
new value of 540 nm. This indicates that the enzymes have successfully immobilised onto
the particles, as the λ-max of gold nanoparticles is directly correlated to the overall size of
the nanoparticle, therefore by increasing the size by conjugating enzymes onto the surface
of the nanoparticle the overall λ-max of the UV-vis spectra will increase [15]. YfkO-cys is
presented here as an example, but the same results were observed when using NfnB-cys.
Next, the natu f the binding of the cys-tagg d enzymes to a gold surface was
evalu ted using cyclic voltammetry, based on the change in the go d reduction peak after
immobilisation (Figure 4).
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reduction cycles of an Au(111) coated glass slide after 48 h incubation with YfkO-cys: scan 1 (solid line) = −959.47 mV,
−32.60 µA and scan 2 (dashed line) = −959.47 mV, −21.82 µA. The potential is vs. SCE in an electrolyte of 0.1 M NaOH.
The volta mogram exhibits the characteri ti t i eak at roughly 980 mV that
i associated with thiol desorption [37]; ther fi i that the cys-tag ed enzymes
were successfully bound to the surface of t f ce via thiol bonds. This allows us
t conclude that th enzymes were also i ilis t the surface of the gold-coated
iron nanoparticles via thiol bonds. Again, hile Yfk -cys has been shown as the example
here, the same results were also seen for NfnB-cys.
3.3. Enzyme Reactivity with CB1954
Once purified, the proteins were tested for their reactivity towards CB1954 and ability
to reduce its nitro groups. Active proteins would be able to reduce CB1954 to either the 2-
or 4-hydroxylamine derivatives in the presence of a cofactor, which in this case was NADH.
This could be monitored using UV-Visible spectroscopy as with each scan for an active
protein the peak corresponding to NADH would decrease (λ-max = 340 nm) and the peak
corresponding to the CB1954 hydroxylamine derivatives would increase (λ-max = 420 nm)
(Figure 5).
All enzymes were shown to be active with the CB1954 prodrug when tested in this
way. Furthermore, all enzymes retained their activity when immobilised to the Au-MNPs
(Figure 6).
The UV-Vis activity scans for YfkO-cys have been presented as an example here, but
the scans obtained for NfnB-cys, free and immobilised, were almost identical to these.
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3.4. Michaelis-Menten Kinetics
Using the hyperbola regression analysis tool in SigmaPlot, the Michaelis-Menten
kinetic param ters w th re pect to var ing conce trations of CB1954 at 37 ◦C were estab-
lished using the absorbance of the CB1954 hydroxylamine derivatives at 420 nm (Table 1).
This was done for both free and immobilised YfkO-cys and compared to our previously
published data for free and immobilised NfnB-cys [32].
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Table 1. Michaelis-Menten data obtained for free and immobilised YfkO-cys with varying concentrations of CB1954,
compared to the data we have published previously for free and immobilised NfnB-cys [32].
Enzyme Vmax (µM s−1) Km (µM) Kcat (s−1) Kcat/Km (µM−1 s−1)
NfnB-cys 19.4 ± 1.3 5000 ± 700 55.34 ± 0.57 0.0109 ± 3.8 × 10−3
Immobilised NfnB-cys 10.89 ± 1.2 1108 ± 300 61.85 ± 0.64 0.0558 ± 3.5 × 10−3
YfkO-cys 6.5 ± 1.2 830 ± 250 39.34 ± 0.89 0.0471 ± 3.6 × 10−3
Immobilised YfkO-cys 8.35 ± 1.4 1374 ± 400 50.30 ± 0.78 0.0366 ± 3.7 × 10−3
When comparing the Michaelis-Menten kinetic data obtained for free and immobilised
YfkO-cys with the data obtained previously, there are several interesting observations.
Firstly, when comparing the two enzymes free in solution, it is evident that YfkO-cys
is much more efficient in its reaction with the CB1954 (Kcat/Km = 0.0471 µM−1 s−1
for YfkO-cys compared to 0.0109 µM−1 s−1 for NfnB-cys) which is four times greater
in efficiency where Kcat is the rate of catalytic conversion and Km is 12 of Vmax which
is, itself the maximum rate of the system. This was predominately caused by the fact
that YfkO-cys has a much higher affinity for the CB1954 prodrug as evidenced by the
lower Km (Km = 834.33 µM for YfkO-cys compared to 5078.37 µM for NfnB-cys). The
next notable finding is that, unlike previously for NfnB-cys [32], when YfkO-cys was im-
mobilised onto the nanoparticles it became less efficient in its reaction with the CB1954
(Kcat/Km = 0.0366 µM−1 s−1 for free YfkO-cys compared to 0.0471 µM−1 s−1 for immo-
bilised YfkO-cys). This is because, despite the fact that immobilised YfkO-cys demonstrated
a higher turnover of the CB1954 (Kcat = 39.34 s−1 for free YfkO-cys compared to 50.30 s−1
for immobilised YfkO-cys), the Km increased by more than half once it was immobilised
onto the nanoparticles (Km = 834.33 µM for free YfkO-cys compared to 1374.59 µM for
immobilised YfkO-cys).
3.5. HPLC of CB1954 Products
Following the method we have previously described [32] the CB1954 hydroxylamine
product ratio was assessed for free and immobilised YfkO-cys and compared to the previ-
ously published results for free and immobilised NfnB-cys, these values can be seen below
in Table 2 [32].
Table 2. The ratio of hydroxylamine derivatives formed upon reacting free and immobilised YfkO-cys,
compared to those we have previously published for NfnB-cys [32].





The hydroxylamine product ratios produced by free (4:96) and immobilised (1:99)
YfkO-cys were both extremely similar to one another, and in both cases, the enzyme demon-
strated a preference for reducing CB1954 at the 4-nitro position. This result is of clinical
significance because the 4-hydroxylamine product has been shown in the literature to be
further reduced by intracellular thioesters, like Acetyl Coenzyme A, to form a compound
able to cross-link DNA [8,12,24].
3.6. Cell Viability Assays
Percentage cell viability assays were carried out using the ovarian cancer cell line,
SK-OV-3, relative to untreated controls, in the presence of increasing concentrations of
free or immobilised NfnB-cys or YfkO-cys, with a constant concentration of CB1954 added
(Figure 7). The controls used were cell culture medium only, the enzyme only and prodrug
only, and data points were plotted based on the averages of at least three repeats. The
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CB1954 concentration was fixed at 10 µM so that the results of the cell viability assays could
be related to clinical results. The maximum concentration of CB1954 achievable in vivo
cannot exceed 10 µM, due to the maximum tolerated dose established during clinical
trials [21,38,39].
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Figure 7. Percentage cell survival relative to untreated control cells of SK-OV-3 cells after a 4 h incubation with prodrug only,
enzyme only and increasing concentrations of either free or immobilised NfnB-cys or YfkO-cys (25–200 nM) in presence
of CB1954 (10 µM). All data points are taken from the averages of at least three repeats and the error bars represent the
standard deviation. Data points were analysed for their statistical significance using F-test with a p value of (>0.005), error
bars are ±1 standard deviation, and (n) is the number of repeats each data point had.
Promisingly, no significant cell killing was observed when the cells were treated
with either the prodrug alone or the enzyme alone. Upon being treated with the lowest
concentration of enzyme (25 nM) plus prodrug, there was an immediate response for
all combinations—with cell viabilities between 70% and 80%. The data was analysed
for statistical significance by F-test with all data sets demonstrating levels of statistical
significance (p < 0.005). Immobilised YfkO-cys produced the most potent response at this
conce tration, whereas free NfnB-cys produced the weakest response. For all combinations,
there was an initial decrease in the cell killing potency w n th enzyme concentration was
increased from 25 to 50 nM, before the cell killing potency increas d again as the enzyme
co centration approache 200 nM. Whilst this appears to be contrary to what might be
expected, it could be attributed to a well-documented effect, known as the Hormetic
effect [40]. The Hormetic effect is evident from the characteristic inverted- U-shaped
response on the graph [40], and it is a phenomenon that we have come to expect when
testing CB1954’s cell killing potency in SK-OV-3 cells [32–34].
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4. Discussion
The major aim of this study was to assess the YfkO nitroreductase as an alternative to
the heavily investigated NfnB nitroreductase for use in MNDEPT treatments in terms of
their ability to reduce the CB1954 prodrug and cause cell death in cancerous cell lines when
immobilised on to the Au-MNPs. Furthermore, it was also hoped that the genetically mod-
ified YfkO-cys NTR would produce a more favourable ratio of the CB1954 hydroxylamine
derivatives and be superior in terms of its kinetic activity with CB1954 when compared to
the corresponding NfnB.
Gold-coated Iron Nanoparticles (AuMNPs) were successfully synthesized and puri-
fied, and their size was confirmed to be roughly 50 nm in size using TEM. We have shown
in previous work that AuMNPs of this size can be directly uptaken into cancerous cells
via endocytosis [33], so this is significant because it means that, if we could form active
AuMNP-NTR conjugates, we would have a prodrug-activating system capable of being
uptaken into cancerous cells where it could access intracellular cofactor and facilitate the
production of the toxic CB1954 products.
The genetically modified cys-tagged enzymes were designed previously [15] with
intention of immobilizing them directly onto the surface of the AuMNPs for use in MN-
DEPT strategies, so we then needed to test if we were able to successfully form AuMNP-
NTR conjugates.
It is well established from previous work [15] that when you immobilize enzymes
onto the surface of nanoparticles, increasing the overall size, there is a red-shift in the
λ-max of the gold peak. In this work, when immobilizing YfkO-cys onto the nanoparticles,
we observed a red-shift of 4 nm, indicating successful conjugation.
Next, we had to establish if the conjugation was via thiol-bonds as intended. Cyclic
voltammetry was used to analyse the cys-tagged enzymes that had been immobilised onto
gold slides to see if they formed thiol bonds, based on the change in the gold reduction
peak after immobilisation. The voltammogram exhibited the characteristic cathodic peak
at roughly 980 mV that is associated with thiol desorption onto a gold surface [37]. Based
on this, we concluded that enzymes had been immobilised to the AuMNPs via thiol bonds.
This is an important result because the cys-tags have been placed on the N-terminus of the
enzyme deliberately so that the active site of the enzyme remains accessible by substrates
once immobilised [15].
After analysing all the enzymatic activity scans, it was clear that YfkO-cys was able
to readily reduce CB1954 to its hydroxylamine derivatives in the presence of NADH as a
cofactor, whether the enzyme was free in solution or immobilised onto the nanoparticles.
Again, the fact that the enzyme remains active when immobilised, is further evidence of the
formation of thiol bonds onto the surface of the AuMNPs because it shows immobilization
took place away from the active site, as intended.
The kinetic data obtained for YfkO is not in agreement with the data reported in the
literature due to the fact that this data set was generated using NADH as the cofactor
whereas Prosser et al. [14] reported Kcat/Km = 0.025 µM−1·s−1 for this enzyme using
NADPH as the cofactor. NADH was chosen as the cofactor for this data set because it
is much more abundant intracellularly than NADPH [41] and it allowed a more direct
comparison to the data previously generated for the corresponding NfnB [32]. Despite
the differences in values for Kcat/Km, the data reported in this study does agree with the
literature in the sense that the reported Kcat/Km for YfkO is greater than that of NfnB
free in solution, indicating that the reaction with CB1954 is more efficient when using this
enzyme. Unfortunately, the YfkO enzyme did not remain more efficient than NfnB when
immobilised onto the AuMNPs. However, the YfkO/CB1954 combination is still likely to
perform better in a clinical setting than the NfnB/CB1954 combination because the YfkO
enzyme reduces CB1954 almost exclusively at the 4-nitro position, meaning that it will
produce much more of the DNA-reactive species that have been identified in previous
literature [8,12,24]. Alternatively, some literature has suggested that there are benefits to
using enzymes which favour the reduction of CB1954 at the 2-hydroxylamine position
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because the products formed from that reaction have a higher bystander effect than those
formed after reaction at the 4-hydroxylamine position [21,42,43].
Cell viability assays carried out by Vass et al. on the SK-OV-3 cell line appeared to show
superior results in terms of the cell viability after treatment compared to the data reported
in this study [44]. An explanation for this difference in reported cell viability is that, in
their work, they incubated their cells with the additional cofactor (NAD(P)H) whereas in
this dataset only the intracellular cofactor is used, with no additional cofactor being added
as this gives a better indication of how the treatment will perform in vivo [32–34]. The fact
that a killing of the cells was observed indicates that the treatment was successfully up
taken into the SK-OV-3 cells, where it could access the intracellular cofactor to produce toxic
products and induce cell death. It is promising that, of all combinations tested, immobilised
YfkO-cys performed the best at the lowest concentration of enzyme tested and this is likely
because it almost exclusively reduced CB1954 at the 4-hydroxylamine position, leading to
the production of the highly potent DNA cross-linking species. The Anova test was used
to asses if each overall set of cell viability contained significant data using a significance
level (p-value) of 0.005 (99.5% confidence level), the F-value for each set of cell culture
data as larger than the fcritical-value produced by the Anova test, indicating statistically
significant results.
5. Conclusions
In conclusion, YfkO-cys and NfnB-cys have both been shown to be active with the
CB1954 prodrug. Furthermore, both enzymes were successfully immobilised onto the novel
AuMNP prodrug-activating enzyme delivery system that we have developed in-house and
retained their activity with the prodrug once immobilised. YfkO-cys has been identified
as a promising candidate for use in DEPT treatments using CB1954 as it has been shown
to reduce CB1954 predominately at the more desirable 4-hydroxylamine position, which
leads to the formation of DNA-reactive species when reacted with intracellular thioesters.
The next stage of this research will be to use immobilised YfkO-cys in combination with
cell-penetrating peptides in 3D cell culture models, as we have shown previously that these
can increase the cellular uptake of nanoparticle based treatments [33]. We expect that this
will see the cell killing potency of the YfkO-cys/CB1954 increase drastically as more of the
enzyme will have access to the intracellular cofactor present within the cells, leading to the
formation of more of the toxic CB1954 products.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/pharmaceutics13040517/s1, Figure S1: HPLC chromatogram for YfkO-Cys, Figure S2: HPLC
chromatogram for NfnB-Cys, Figure S3: HPLC chromatogram for Immobilized YfkO-Cys, Figure S4:
HPLC chromatogram for Immobilized NfnB-Cys, Figure S5: HPLC of a CB1954 standard, Figure S6:
HPLC of a nitroreductase standard, Figure S7: HPLC of a NADH standard, Figure S8: HPLC of a
NAD+ standard.
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